论文部分内容阅读
Teicoplanin(T)是一与万古霉素(V)结构类似的新的糖肽类抗生素,体外抗菌活力试验表明,对金葡球菌,T 比V 高2～4倍,对链球菌则为4～8倍。英国和意大利对T 的药代动力学及其在临床初步试验进行了研究。8例健康男性受试者注射T 200mg 5天以上。第一序程每12h 注射一次共3次,第二疗程每24h 注射一次共3次。注射后吸收迅速,1h 后血浆浓度为2.8±0.5mg/1,4±0.8h 可达峰值7.1±0.8mg/l;第二疗程峰值达12.1±0.9 mg/l,其消除半衰期为99±2.8h。Teicoplanin 的尿浓度于1～7天时为16～156mg/l,
Teicoplanin (T) is a new glycopeptide antibiotic with similar structure to vancomycin (V). The in vitro antibacterial activity test shows that T is 2 to 4 times higher than V to Staphylococcus aureus and 4 ~ 8 times. Pharmacokinetics of T in the United Kingdom and Italy and its preliminary clinical trials were studied. Eight healthy male subjects were given T 200 mg for 5 days or more. The first sequence of injection once every 12h a total of 3 times, the second course of injection of a total of 3 times every 24h. After 1h, the plasma concentration was 2.8 ± 0.5mg / 1,4 ± 0.8h up to 7.1 ± 0.8mg / l; the second treatment peak reached 12.1 ± 0.9 mg / l, the elimination half-life was 99 ± 2.8 h Urinary concentrations of Teicoplanin ranged from 16 to 156 mg / l at days 1 to 7,